Plain-English translation of NCT06774326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether a specialized CT scan called Spectral CT can detect early signs of heart damage in patients receiving anthracycline chemotherapy for Hodgkin's lymphoma or diffuse large B-cell lymphoma. The new scan uses advanced imaging technology to look inside heart tissue and spot changes like swelling and scarring that traditional heart tests might miss. If successful, this could help doctors catch heart problems early and start protective treatments before serious damage occurs.
Anthracycline chemotherapy effectively treats certain lymphomas but can damage the heart in ways that develop slowly and may not show up on standard heart tests until significant harm has occurred. This trial exists to see if Spectral CT can detect these changes earlier and more reliably than current methods, potentially allowing doctors to intervene sooner and prevent long-term heart problems.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive a Spectral CT scan as part of your routine cancer follow-up appointments. This specialized scan is similar to a standard CT scan but provides more detailed information about your heart tissue. The scan takes place during times when you would already be coming in for cancer monitoring, so participation mainly involves this additional imaging test alongside your regular care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~160 participants
Started
February 2024
Primary completion
August 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Vincenzo Russo, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.